← Back to Home
Short Term·Markets Desk·Yesterday
Short-Term Radar: BALPHARMA Leads 5 Picks for the Coming Weeks
Research desks at Zee Business and Cnbc Awaaz backed 5 stocks for short-term gains over the coming weeks, reflecting a broadly bullish market view.
By Markets Desk·8 Calls·8 Buy
Zee Business and 1 other registered desk issued 8 equity short term recommendations today, targeting gains over a 2 to 4 week horizon. The batch carries a bullish bias — 8 buys against 0 sells — covering 5 stocks.
BALPHARMA was flagged for a buy by Zee Business at ₹1,490, targeting ₹2,274 — a potential upside of +52.6%, with a stoploss at ₹2,207. The risk-to-reward ratio stands at 1:1.1.
KEI attracted 2 separate recommendations from registered analysts — Zee Business issued a buy at ₹5,023.3 targeting ₹5,250; Zee Business issued a buy at ₹5,023 targeting ₹5,250.
LTF attracted 3 separate recommendations from registered analysts — Zee Business issued a buy at ₹318 targeting ₹325 (stop ₹314); Zee Business issued a buy at ₹318 targeting ₹325; Cnbc Awaaz issued a buy at ₹318 targeting ₹400 (stop ₹275).
Also covered: KANSAINER (₹204 → ₹215) via Zee Business; HONASA (₹458 → ₹475) via Cnbc Awaaz.
Short-term calls are designed to play out over two to four weeks. Quarterly results, FII flows, and sector rotation remain key variables during the holding period.
All recommendations reproduced here originate exclusively from SEBI-registered Research Analysts and are published for informational purposes only. These are not buy or sell recommendations from this publication. Registration with SEBI does not guarantee returns. Investing in securities markets is subject to market risks — read all related documents carefully before investing.
Analyst Sources
Zee BusinessCnbc Awaaz
Disclaimer
All recommendations published on Bharatstox are sourced exclusively from SEBI-registered Research Analysts. Registration with SEBI does not guarantee returns or the performance of the intermediary. Investing in securities markets is subject to market risks. Read all related documents carefully before investing. This article is for informational purposes only and does not constitute investment advice.